Cancer Data Project

Johanna Haraldsdottir (s204657), Marie Kragh (s203566), Sofie Bruun (s194678), Amalie Schultz-Nielsen (s204643), and Malou Bech Jakobsen (s203515)

Introduction

  • The Drug data set provides information about various medications: from treatments of cancer and Alzheimer’s disease to common colds and pain relief

  • Purpose: Assist healthcare professionals and patients in making decisions when choosing a medication

  • The 3 rules for making a data set tidy are not satisfied

# A tibble: 11,825 × 3
   `Medicine Name`          Uses                                     Composition
   <chr>                    <chr>                                    <chr>      
 1 Avastin 400mg Injection  Cancer of colon and rectum Non-small ce… Bevacizuma…
 2 Augmentin 625 Duo Tablet Treatment of Bacterial infections        Amoxycilli…
 3 Azithral 500 Tablet      Treatment of Bacterial infections        Azithromyc…
 4 Ascoril LS Syrup         Treatment of Cough with mucus            Ambroxol (…
 5 Aciloc 150 Tablet        Treatment of Gastroesophageal reflux di… Ranitidine…
 6 Allegra 120mg Tablet     Treatment of Sneezing and runny nose du… Fexofenadi…
 7 Avil 25 Tablet           Treatment of Allergic conditionsTreatme… Pheniramin…
 8 Aricep 5 Tablet          Alzheimer's disease                      Donepezil …
 9 Amoxyclav 625 Tablet     Treatment of Bacterial infections        Amoxycilli…
10 Atarax 25mg Tablet       Treatment of AnxietyTreatment of Skin c… Hydroxyzin…
# ℹ 11,815 more rows

Materials and Methods

Cleaning

Augmentation

Description of the Cancer Data

  • Variables:
    Medicine name
    Composition
    Uses
    Side effects
    Manufacturer
    Poor, Average, Excellent reviews (%)

  • Distribution of Side Effects

Hej

Analysis 1: Review Levels

What are the probable causes behind the excellent, average, and poor reviews for the cancer drugs?

Influence of Number of Side Effects

Influence of Administration Type

Analysis 2: The 10 most prevalent medications

Results Analysis Three

skriv bullets points

Conclusion

Discussion

Keep in Mind

  • Representativeness of data

The Next Steps

  • Augmentation: New administration type categories [Topical, Oral, Parenteral]

  • Analysis of the cancer types